Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Chiesi & Protalix Announce EMA Validation for Pegunigalsidase Alfa Submission
Details : Elfabrio (pegunigalsidase alfa) is a globotriaosylceramide inhibitor enzyme drug candidate, which is being evaluated to label a less frequent dosing regimen for treating fabry disease.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
December 09, 2024
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Elfabrio (pegunigalsidase alfa-iwxj) is a PEGylated enzyme replacement therapy (ERT) for the treatment of adult patients with Fabry disease. It is a recombinant human α–Galactosidase–A enzyme expressed in plant-cell culture that is designed to provi...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
October 05, 2023
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX-102 (pegunigalsidase alfa), EC authorized, is a novel PEGylated, covalently crosslinked form of α-galactosidase-A developed as enzyme replacement therapy for fabry disease, was designed to increase plasma half-life and reduce immunogenicity, thereby...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
May 05, 2023
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : PRX-115
Therapeutic Area : Rheumatology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX-115 is a PEGylated enzyme expressed via ProCellEx® for intravenous (IV) administration of recombinant Uricase, designed for safe and efficacious treatment of refractory gout
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 21, 2023
Lead Product(s) : PRX-115
Therapeutic Area : Rheumatology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 (pegunigalsidase alfa) a novel PEGylated, covalently crosslinked form of α-galactosidase A developed as enzyme replacement therapy for fabry disease, was designed to increase plasma half-life and reduce immunogenicity, thereby enhancing effica...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
February 24, 2023
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
November 14, 2022
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRX–102 (pegunigalsidase alfa) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme. It is a novel, PEGylated ERT under development for the treatment of Fabry d...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
May 12, 2022
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from the clinical development programme developed with Protalix BioTherapeutics evaluating pegunigalsidase alfa (PRX-102) an investigational enzyme replacement therapy (ERT), support its potential as a treatment option for adult patients with Fab...
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
February 09, 2022
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Recipient : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pegunigalsidase alfa (PRX–102) is an investigational, plant cell culture-expressed, and chemically modified stabilized version of the recombinant α–Galactosidase–A enzyme. Protein sub-units are covalently bound via chemical cross-linking using sho...
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
November 10, 2021
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Chiesi Group
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Following the switch to pegunigalsidase alfa there was a decrease in patients with progressing or fast progressing kidney disease, and the majority of patients achieved a stable status post-switch.
Product Name : Elfabrio
Product Type : Enzyme
Upfront Cash : Inapplicable
October 02, 2021
Lead Product(s) : Pegunigalsidase Alpha
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable